Cefoxitin
Based on 12 publication(s) in Google Scholar
Cefoxitin is a cephalosporin-class antibiotic. Cefoxitin is highly stable against β-Lactamase (HY-P2998). Cefoxitin has a broad spectrum of antibacterial activity, including Gram-negative and Gram-positive bacteria.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.92%
- No. CAS: 35607-66-0
- Fòrmula: C16H17N3O7S2
- Peso molecular:427.45
-
Almacenamiento:
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Antibacterial Compound Library
HY-L049
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Human Metabolite Library
HY-L123
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Anti-Infection Compound Library
HY-L002
-
FDA-Approved Drug Library
HY-L022
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Cefoxitin
More- Nat Microbiol. 2023 Mar;8(3):410-423. [Abstract]
- Nat Commun. 2023 Mar 22;14(1):1594. [Abstract]
- Nat Commun. 2022 Mar 2;13(1):1116. [Abstract]
- Food Res Int. 2026 Aug 31:238:119421. [Abstract]
- J Clin Microbiol. 2025 Aug 20:e0084125. [Abstract]
- Antimicrob Agents Chemother. 2025 Jul 2;69(7):e0024925. [Abstract]
- J Antimicrob Chemother. 2025 Nov 5:dkaf408. [Abstract]
- Microbiol Spectr. 2025 Jul;13(7):e0307424. [Abstract]
- J Antimicrob Chemother. 2020 Jul 1;75(7):1850-1858. [Abstract]
- Infect Drug Resist. 2025 Oct 4:18:5239-5247. [Abstract]
- Diagn Microbiol Infect Dis. 2026 Feb;114(2):117181. [Abstract]
- bioRxiv. 2025 Jun 19.
Ver todos los productos específicos de isoformas Antibiotic
MoreVer todos los productos específicos de isoformas Beta-lactamase
More
Actividad biológica
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| CHO | IC50 |
57 μM
Compound: Cefoxitin
|
Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins
Inhibition of mouse OAT3 expressed in CHO cells assessed as inhibition of fluorescein uptake over 20 mins
|
[PMID: 23344796] |
Cefoxitin (0-160 μM; 72 h) has MICs of 0.625 μM (for strains CA8 and JLB31) and 1.25 μM (for strain NP40) against three strains of B. burgdorferi[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Four-week-old female C3H/HeN mice[3]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection, daily, for five consecutive days
-
Result:Had shown high efficacy killing B. burgdorferi. B. burgdorferi was not detected in the tissue samples of the ears, urinary bladders, and hearts of the mice.
Chemical Information
-
No. CAS 35607-66-0
-
Appearance Solid
-
Peso molecular 427.45
-
Fòrmula C16H17N3O7S2
-
Color White to off-white
-
SMILES
O=C(C(N12)=C(COC(N)=O)CS[C@]2([H])[C@@](NC(CC3=CC=CS3)=O)(OC)C1=O)O
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture and light
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
Publications (12)
-
Journal Impact Factor
-
Most Recent
-
Nat Microbiol
Characterization of antibiotic resistomes by reprogrammed bacteriophage-enabled functional metagenomics in clinical strains. [Abstract]2023 Mar;8(3):410-423. PMID: 36759752 -
Nat Commun
2023 Mar 22;14(1):1594. PMID: 36949052 -
Nat Commun
Antimicrobial resistance and population genomics of multidrug-resistant Escherichia coli in pig farms in mainland China. [Abstract]2022 Mar 2;13(1):1116. PMID: 35236849 -
Food Res Int
Prevalence, plasmid transmission, and chromosomal integration of blaCTX-M genes in Salmonella isolated from retail chicken and pork meats in China. [Abstract]2026 Aug 31:238:119421. PMID: 42215089 -
J Clin Microbiol
Luciferase reporter mycobacteriophage (TM4:: GeNL) enables rapid assessment of drug susceptibilities and inducible macrolide resistance in Mycobacterium abscessus complex. [Abstract]2025 Aug 20:e0084125. PMID: 40833127 -
Antimicrob Agents Chemother
An enoyl-ACP reductase inhibitor, NITD-916, expresses anti- Mycobacterium abscessus activity. [Abstract]2025 Jul 2;69(7):e0024925. PMID: 40407337 -
J Antimicrob Chemother
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction. [Abstract]2025 Nov 5:dkaf408. PMID: 41206063 -
Microbiol Spectr
Antimicrobial resistance of rapidly growing mycobacteria isolated from companion animals in Taiwan. [Abstract]2025 Jul;13(7):e0307424. PMID: 40387379 -
J Antimicrob Chemother
In vitro activity of the novel β-lactamase inhibitor taniborbactam (VNRX-5133), in combination with cefepime or meropenem, against MDR Gram-negative bacterial isolates from China. [Abstract]2020 Jul 1;75(7):1850-1858. PMID: 32154866 -
Infect Drug Resist
In vitro Activity of the Novel Tetracyclines Derivative, Zifanocycline Against Mycobacterium abscessus. [Abstract]2025 Oct 4:18:5239-5247. PMID: 41069760 -
Diagn Microbiol Infect Dis
2026 Feb;114(2):117181. PMID: 41205476 -
Solvente y solubilidad
DMSO : 100 mg/mL (233.95 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.85 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (275 KB)
-
SDS (418 KB)
- English - EN (418 KB)
- Français - FR (418 KB)
- Deutsch - DE (418 KB)
- Norwegian - NO (418 KB)
- Español - ES (418 KB)
- Swedish - SV (418 KB)
- Italian - IT (418 KB)
- Korean - KR (418 KB)
- Portuguese - PT (418 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. E O Stapley, et al. Cefoxitin and cephamycins: microbiological studies. Rev Infect Dis. Jan-Feb 1979;1(1):73-89. [Content Brief]
[2]. R N Brogden, et al. Cefoxitin: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs. 1979 Jan;17(1):1-37. [Content Brief]
[3]. Venkata Raveendra Pothineni, et al. In vitro and in vivo evaluation of cephalosporins for the treatment of Lyme disease. Drug Des Devel Ther. 2018; 12: 2915–2921. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.3395 mL | 11.6973 mL | 23.3945 mL | 58.4864 mL |
| 5 mM | 0.4679 mL | 2.3395 mL | 4.6789 mL | 11.6973 mL | |
| 10 mM | 0.2339 mL | 1.1697 mL | 2.3395 mL | 5.8486 mL | |
| 15 mM | 0.1560 mL | 0.7798 mL | 1.5596 mL | 3.8991 mL | |
| 20 mM | 0.1170 mL | 0.5849 mL | 1.1697 mL | 2.9243 mL | |
| 25 mM | 0.0936 mL | 0.4679 mL | 0.9358 mL | 2.3395 mL | |
| 30 mM | 0.0780 mL | 0.3899 mL | 0.7798 mL | 1.9495 mL | |
| 40 mM | 0.0585 mL | 0.2924 mL | 0.5849 mL | 1.4622 mL | |
| 50 mM | 0.0468 mL | 0.2339 mL | 0.4679 mL | 1.1697 mL | |
| 60 mM | 0.0390 mL | 0.1950 mL | 0.3899 mL | 0.9748 mL | |
| 80 mM | 0.0292 mL | 0.1462 mL | 0.2924 mL | 0.7311 mL | |
| 100 mM | 0.0234 mL | 0.1170 mL | 0.2339 mL | 0.5849 mL |
Cefoxitin Related Classifications
HY-B1825 Related Classifications
Powered by Bioz